Floatz logo

Ispinesib

Refractory Anemia With Excess Blasts in Transformation

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Refractory Anemia With Excess Blasts in Transformation cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
National Cancer Institute (NCI)
Phase 3BBB
FILGRASTIM
Masonic Cancer Center, University of Minnesota
Phase 3BBB
Fludarabine
Nohla Therapeutics, Inc.
Phase 3BB
Idarubicine
National Cancer Institute (NCI)
Phase 3BB
Daunorubicin
National Cancer Institute (NCI)
Phase 3BB

View all 32 →

Same molecule, other indications

Ispinesib is also rated in:

breast cancerDormant
B
Indicative ·
57 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
57 / 100
View asset →
colon carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →